Browse Companies

Century Therapeutics employs induced pluripotent stem cells combined with their Allo-Evasion™ gene editing platform to develop off-the-shelf allogeneic therapies targeting autoimmune diseases and cancer. The company has notably reduced its operating losses by over 80% year-over-year while advancing its lead candidate CNTY-813 for type 1 diabetes into IND-enabling studies. Despite robust liquidity and integrated manufacturing capabilities, Century faces clinical, manufacturing, and regulatory execution risks typical of emerging cell therapy developers. Upcoming clinical milestones and manufacturing scale validation represent critical inflection points for the firm’s transition toward commercialization readiness.

Odyssey Health, Inc. remains a development-stage medical technology company without revenue to date, driven historically by its unique product candidates: the CardioMap heart monitoring device and the Save-A-Life choking rescue device. Persistent operating losses, negative cash flow, and substantial current liabilities have pressured liquidity and raised going concern doubts. The company’s strategic divestiture of its neurological drug assets to Oragenics and recent market expansion efforts point to a transitional phase toward commercialization. Critical upcoming milestones hinge on securing FDA regulatory clearances and successful clinical outcomes, while continued capital raises remain essential to sustain operations.

MBX Biosciences, focused on peptide therapeutics for metabolic diseases, recorded a net loss of $86.97 million in 2025 amid intensifying R&D and operational expenses. The company’s cash reserves of approximately $75.3 million support ongoing operations into 2029 under current plans. Its clinical pipeline includes three main candidates, with plans to add two obesity-related therapies in 2026. MBX relies on exclusive intellectual property licensed from Indiana University Research and Technology Corporation, forming a core competitive asset. While facing typical biotech risks including regulatory uncertainties and capital requirements, recent insider buying signals management confidence despite market caution.

TIC Solutions, Inc. has recently completed the acquisition of NV5 Global, significantly broadening its service offerings and expanding its government-related contract base. Operating predominantly through short-duration contracts with U.S. federal and state agencies—especially in California—the company faces revenue variability linked to government budget uncertainties and procurement cycles. TIC’s business model emphasizes flexibility but depends heavily on public-sector funding rhythms. Strong liquidity supports operational resilience, while leadership transition and integration execution remain key near-term focus areas.

Verano Holdings operates one of the largest vertically integrated cannabis platforms in the U.S., spanning cultivation, processing, wholesale, and retail across 13 states. Its diversified footprint and consumer brand portfolio support resilience amid the fragmented state-by-state legalization landscape. However, recent financials reveal sustained operating losses and net losses despite progress toward narrowing deficits. The company’s liquidity position remains stable with substantial current assets exceeding liabilities, supported by recent refinancing activity. Regulatory risks, federal illegality of cannabis, and cost pressures on margins continue to cap upside potential and cloud growth visibility.

Coffee Holding Co. Inc. (JVA) operates as an integrated wholesale coffee roaster and dealer focusing on wholesale green coffee, private label, and branded products in the U.S. and select Asian markets. The company has faced significant volatility in profitability over recent years, driven by commodity price fluctuations and competitive pressures, but aims to grow through brand development and acquisitions like Empire Coffee Company. While the firm shows operational resilience with strategic consolidation of manufacturing, recent financials reveal a sharp decline in operating cash flow and free cash flow deficits. Key risks include reliance on coffee as a single commodity, customer concentration, and supply chain uncertainties.

Theriva Biologics continues to develop its lead oncolytic virus candidate VCN-01 for metastatic pancreatic cancer, supported by FDA Fast Track and Rare Disease designations. Despite operational milestones including Phase 2b enrollment completion and licensing deals such as SYN-020 with Rasayana Pharmaceuticals, the company faces ongoing financial strain with no revenue, an accumulated deficit of approximately $358.7 million, negative operating cash flow of $16.7 million in 2025, and $13.1 million in cash at year-end. Contingent milestone payments and limited runway into early 2027 underscore the need for additional capital to sustain operations. Investors should monitor clinical readouts, milestone developments, and financing strategies closely [F1][N1][N2][N3][S1][S3].

CEA Industries Inc. holds a concentrated digital asset treasury with over 515,000 BNB tokens valued at approximately $403 million as of January 2026. This concentration subjects the company to substantial earnings volatility, evidenced by a $159.8 million unrealized loss on digital assets during Q1 FY2026. Despite steady revenue growth through 2018, the company has posted persistent operating losses and negative cash flows in recent years. Liquidity remains supported by $11.3 million in cash and equivalents and a current ratio of 2.62, but custodial risks and market illiquidity pose challenges. Governance is unsettled due to an activist campaign seeking board expansion, while regulatory uncertainty around BNB’s classification could materially affect liquidity and valuation. Capital allocation reflects constrained conditions with ongoing operating cash flow deficits, minimal capital expenditures, no dividends or buybacks, and an approximate -17% return on equity. The appointment of Brent Miller as CFO signals renewed focus on managing treasury volatility and operational resilience.

Rafael Holdings, Inc. operates at the intersection of biotechnology and medical devices, concentrating on its lead drug candidate Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). The company’s historical revenue growth has been modest but accelerating, while operating losses have narrowed significantly. Its future hinges on successful completion of a pivotal Phase 3 clinical trial, regulatory approvals, and commercialization efforts. Capital allocation remains focused on clinical development with a strong cash position but ongoing high operating cash burn. Regulatory and market risks inherent to rare disease therapeutics and med-tech sectors add complexity to Rafael’s outlook.

U.S. GOLD CORP., a development-stage precious metals explorer, continues progressing its flagship CK Gold Project in Wyoming with focused engineering and permitting studies, while managing fluctuating operating costs and exploration outlays. The company reported sustained net losses and negative cash flow but boosted liquidity through a significant $31.2 million private placement in December 2025, enhancing working capital substantially. Despite this infusion, the company faces material going concern risks given its lack of revenue and dependence on future financings to fund project advancement beyond feasibility studies.

After several years of operational losses, RF Industries Ltd consolidated its reportable segments into a unified business model, achieving improved operating income and modest net profitability in fiscal 2025. The company faces ongoing legal and trade risks but maintains strong liquidity with a current ratio of 1.8 as of January 31, 2026. Strategic restructuring aims to streamline manufacturing and sales functions to capture growth opportunities in telecommunications and OEM interconnect solutions.

Zedge, Inc. operates digital marketplaces and skill-based games focused on mobile personalization content and creator engagement. The company’s revenue has been relatively stable with a slight decline from $30.1 million in FY2024 to $29.4 million in FY2025, while operating losses narrowed significantly to -$3.2 million. Zedge leverages AI integration and acquisitions such as GuruShots and Emojipedia to diversify monetization but faces intense competition, platform dependency, and regulatory complexities related to AI and privacy. Key financial metrics indicate improving profitability trends supported by positive operating cash flow and increased share repurchases. Going forward, growth depends on efficient user acquisition, premium offering monetization, and adapting to evolving regulatory landscapes.

Comtech Telecommunications Corp has experienced a multi-year decline in revenue and widening operating losses, driven by challenges in its Satellite and Space Communications segment including discontinued product lines and goodwill impairments. The company is executing a transformation plan focusing on operational streamlining and growth in its Allerium cloud services segment. Despite reductions in SG&A expenses and steady R&D investment, negative cash flow persists alongside substantial debt obligations. Liquidity is supported by $32.8 million in cash and revolving credit availability, but debt service commitments exceed $340 million. The board maintains a $100 million share repurchase authorization, though no repurchases occurred amid restructuring efforts and capital preservation.

Summit Midstream Corp’s Q1 2026 update signals operational continuity in its midstream infrastructure business, with cash and current assets exceeding liabilities providing near-term financial breathing room. However, the company remains constrained by high indebtedness exceeding $1 billion as of year-end 2025, and significant exposure to a concentrated customer base and commodity price volatility. Dividend payments on common stock remain suspended, reflecting prioritization of debt reduction and capital reinvestment amid restrictive covenants. The firm’s competitive position derives from ownership of critical gathering and processing assets secured by long-term easements, yet growth depends on customer drilling activity and ability to finance necessary expansions. Key watchpoints include upstream production trends, commodity price shifts influencing throughput volumes, resolution of the Fiberspar litigation trial in April 2026, and management’s execution in managing leverage within increasingly complex credit markets.

Since its IPO, Franklin BSP Capital Corp has achieved strong growth in net income and portfolio scale, driven notably by the transformative merger with Franklin BSP Lending Corporation in January 2024. The company maintains a focused investment strategy targeting primarily senior secured loans to U.S. middle market companies, with over 80% portfolio concentration in this segment as of year-end 2025. Its capital structure features multiple credit facilities and note issuances aligned with regulatory asset coverage standards, supporting prudent leverage and flexible financing. While distributions have scaled consistently, sustainability may be challenged by credit risks inherent in the middle market loan portfolio and incentive fee structures. Key future milestones include monitoring NAV trends, debt facility utilizations, and performance of recently expanded loan assets.

Innovative Designs Inc has reversed historical losses to achieve significant profitability, doubling revenues over three years largely due to growth in its House Wrap product line powered by proprietary Insultex material. The company is transitioning from outsourced manufacturing to internal Insultex production to enhance margin control and supply reliability, although execution risks persist. Seasonality and geographic concentration weigh on revenue consistency amid stiff competition from established large players. Strong liquidity and prudent capital allocation underpin the recent financial robustness, with future growth hinged on certification milestones and manufacturing scale-up.

SmartFinancial, primarily operating through its subsidiary SmartBank, maintains a strong regional presence across Tennessee, Alabama, and Florida with 43 locations. Its loan portfolio is concentrated in secured commercial real estate and small-to-medium enterprise commercial lending, which drives both growth and credit risk governance. The company reported a notable 26.4% net income increase in 2024 reflecting effective capital deployment and operational efficiency, supported by prudent liquidity management and regulatory capital buffers. Despite favorable financial metrics and an active buyback program, cautious attention to credit provisioning and interest rate exposure remains warranted as key factors shaping future performance.

Playboy, Inc. reported break-even earnings for Q1 2026, marking a pivotal step in its transition toward a capital-light business model centered on licensing revenues, particularly under its long-term agreement with Byborg. The company’s dual-segment structure leverages direct-to-consumer sales via Honey Birdette alongside broad trademark licensing, including digital content licensed to Byborg and an evolving China joint venture. While global brand recognition and diversified licensing agreements underpin revenue visibility, Playboy faces margin pressures from U.S.-China trade uncertainties and must monitor execution risks related to JV integration and competitive consumer markets.

In Q1 2026, Lifeward reported a 22% revenue decline driven primarily by supply chain constraints affecting AlterG anti-gravity system shipments, partially offset by gains in ReWalk personal exoskeleton sales enabled by expanded payor coverage. Operating losses widened due to a significant one-time IPR&D charge from the Oratech acquisition, reflecting the company's pivot toward integrating new biomedical technologies. Lifeward’s business model centers on advanced robotic exoskeletons primarily for spinal cord injury patients, supplemented by rehabilitation systems acquired via recent strategic transactions. The company faces considerable regulatory complexity and manufacturing challenges amid ongoing cash management efforts but aims to leverage FDA-cleared innovations and expanding distribution partnerships to fuel top-line growth. Watch for developments in reimbursement expansion, clinical trial progress of Oratech assets, and operational execution in scaling AlterG penetration internationally.

In its latest quarterly filing, Teads Holding Co. disclosed the first full quarter results following its acquisition, highlighting improvements in operating efficiencies and reduced interest expenses that support margin expansion. The company operates a two-sided omnichannel advertising platform connecting global advertisers with media owners across web, CTV, and app environments, leveraging AI to optimize outcomes. Despite macroeconomic volatility and digital ad ecosystem shifts, Teads's strong relationships and platform capabilities offer competitive advantages. Growth is underpinned by expanding content consumption in CTV and in-app spaces, new ad formats, and advanced audience targeting technologies. The company's liquidity position remains solid amid a sizable debt load incurred from acquisition financing.

Peoples Financial Corp's 2026 Q1 10-Q filing highlights balanced loan portfolio segmentation across residential, construction, nonresidential real estate, and commercial loans, with continued emphasis on CECL-driven credit loss allowances. Despite economic uncertainties impacting key real estate segments, the firm maintains disciplined credit monitoring and allowance buffers. The company’s business model leverages local market knowledge and relationship banking, supporting a modest moat centered on credit risk management. Growth is driven by measured loan demand and dividend sustainability, while risks remain concentrated in economic sensitivity of collateral values and regulatory compliance. Upcoming quarterly results and credit metrics will be critical to assessing operational resilience.

In its latest 10-Q filing dated May 12, 2026, Giftify highlighted continued efforts to integrate its recently acquired CardCash gift card exchange platform alongside the newly merged Takeout7 into its Restaurant.com division. These moves aim to scale transaction volume through enhanced AI-driven processing efficiency and broaden market reach via branded partnerships. While maintaining a roughly balanced liquidity position with $4.2 million cash against similar current liabilities, Giftify faces risks including Nasdaq listing pressure and ongoing net losses. The company's growth hinges on successful platform convergence, operational leverage from machine learning applications, and expanding merchant and consumer network effects in both gift card resale and restaurant discount spaces.

Natural Resource Holdings, Inc. (“NRHI”) has maintained a flat revenue profile since FY2018 alongside ongoing negative operating and net income through FY2025. The company’s equity position remains deeply negative and current liabilities substantially exceed current assets as of early 2026. NRHI’s status exempts it from detailed risk factor disclosures, and no legal proceedings are reported. The absence of material business updates or guidance leaves the outlook uncertain, hinging on potential capital injections or asset acquisitions to alter its financial trajectory.

Protalix BioTherapeutics, a commercial-stage biopharmaceutical firm specializing in plant cell-based recombinant protein therapies, reported a slight decline in revenue to $52.7 million in FY2025 along with a net loss of $6.6 million, reflecting increased costs and operating challenges. Its business centers on enzyme replacement therapies for rare diseases, marketed globally through key collaborations with Pfizer, Chiesi, and Fiocruz. Meanwhile, pipeline expansion efforts focus on rare kidney conditions with PRX-115 advancing into Phase 2 clinical trials. The company’s proprietary ProCellEx® platform and extensive patent portfolio underpin its competitive moat, but regulatory uncertainties and geopolitical risks in Israel remain notable threats to near-term growth and operational stability.

Cingulate Inc. is a clinical-stage biopharmaceutical company focused on innovative once-daily stimulant formulations for ADHD and anxiety treatment. Despite substantial losses totaling over $132 million since inception, the firm is advancing its lead candidate CTx-1301 with an NDA accepted by the FDA and a target regulatory decision date in May 2026. The company remains pre-revenue, heavily reliant on equity and debt issuances for funding, with approximately $11 million in cash at the end of 2025. Investors should monitor the upcoming FDA decision and the company's ability to secure continued capital to sustain operations.

Vyome Holdings, Inc. reported revenue of approximately $320 thousand in FY2025 against sustained net losses exceeding $10 million. The strategic merger with ReShape Lifesciences in mid-2025 introduces potential synergies but also operational complexities amid ongoing clinical development delays. Core clinical assets VT-1953 and VB-1953 approach pivotal regulatory milestones with orphan drug designations enhancing exclusivity prospects. Liquidity remains constrained at roughly $5 million cash with a near 2x current ratio, necessitating prudent capital management including convertible note acquisitions via subsidiary LiveChain. Execution risks persist due to the company's limited commercialization history and clinical trial uncertainties, setting the stage for critical FDA interactions in H1 2026.

In fiscal 2025, Bob's Discount Furniture posted a 16.8% revenue increase to $2.368 billion driven by new store openings and solid comparable sales gains, while successfully leveraging operational efficiencies. Concurrently, the company's February 2026 IPO raised $302.7 million in net proceeds utilized primarily to prepay substantial term loan debt, significantly de-leveraging the balance sheet. Despite headwinds from fluctuating tariffs on imported furniture goods, Bob's maintained gross margin resilience through vendor collaboration and pricing strategies. Looking ahead, ongoing store expansion, enhanced eCommerce penetration, and vigilant tariff management remain key growth levers amidst competitive retail dynamics.

Estrella Immunopharma reported in its May 2026 10-Q that its lead immunotherapy candidate, EB103, has advanced to Phase II following a positive Data Safety Monitoring Board (DSMB) review, marking a crucial development milestone. However, the company continues to grapple with severe liquidity constraints, evidenced by a current ratio of 0.24 with current liabilities vastly outstripping assets, and ongoing Nasdaq compliance issues related to governance timing. As a clinical-stage biotech focused on cancer immunotherapy, Estrella’s value proposition rests on pipeline innovation and clinical outcomes, while its near-term execution is tightly coupled to capital availability and regulatory adherence. Upcoming data readouts and regulatory filings will be key indicators of progress amid these operational headwinds.

Century Casinos posted a significant operating income recovery to $51.3 million in 2025 from a loss in 2024, driven by geographic diversification and operational restructuring. However, the firm continues to report a large net loss of $61.4 million and faces negative shareholder equity primarily due to high leverage and escalating lease obligations to VICI Properties. Liquidity remains constrained with free cash flow turning negative after heavy capital expenditures, while strategic alternatives including potential mergers are under review.

TSS, Inc. specializes in integrating AI-enabled server racks and managing mission-critical facilities, relying heavily on one Fortune 100 OEM customer that accounts for nearly all revenue. The company has invested over $40 million in a state-of-the-art integration facility to support advanced power and cooling requirements critical for AI workloads. While revenue surged sharply in 2025 driven by AI rack services, operating income declined partially due to increased fixed costs and pricing updates. TSS aims to diversify its customer base and increase recurring revenues through maintenance contracts, but the heavy dependence on a single client presents material risks tied to contract changes or volume fluctuations.

In its latest quarterly filing, Mastech Digital highlights consistent delivery in its dual segments of Data and Analytics Services and IT Staffing Services despite typical Q1 seasonality impacting consultant utilization. The company leverages a hybrid onshore-offshore delivery model alongside recent acquisitions to bolster its digital transformation offerings. Client concentration and foreign currency exposure remain notable risks, but strategic share repurchase programs and insider buying underscore management confidence. A strong liquidity position supports ongoing investments to deepen market penetration and service breadth.

Neonode Inc.'s May 2026 10-Q reveals a decisive shift to focus solely on licensing its intellectual property platforms, having exited hardware product sales and moved legacy zForce technology into maintenance mode. The company's revenues depend heavily on nine licensing customers, primarily automotive and consumer electronics OEMs, with persistent risks arising from customer concentration and extended product development cycles. Neonode’s strong patent portfolio supports its competitive moat, yet near-term revenue visibility reflects structural timing delays. With adequate liquidity and minimal debt as of Q1 2026, the company is positioned to fund operations but faces challenges executing growth amid concentrated accounts.

MIND CTI LTD operates as a specialized provider of convergent billing and customer care software tailored for tier 2 and tier 3 telecommunications operators globally. The company’s flagship MINDBill platform, supported by modular architecture and open APIs, enables integration with diverse telecom networks and supports prepaid/postpaid subscriber management. Financially, MNDO experienced a revenue decline of approximately 9.3% in 2025 accompanied by a sharper contraction in earnings, signaling margin pressure despite stable operating cash flow. Growth opportunities hinge on expanding service offerings, including mobile messaging and AI-driven tools, while competition from larger rivals and market volatility pose key risks. The company has discontinued dividends but maintains robust liquidity and operational cash generation.

As a special purpose acquisition company, dMY Squared Technology Group has yet to generate operating revenues, relying on trust account interest income while incurring rising losses primarily due to merger expenses. The pending business combination with Horizon Quantum Holdings offers a strategic pivot into the quantum computing sector but carries substantial execution risks exacerbated by liquidity constraints and multiple deadline extensions. Financial indicators reveal worsening operating losses and a precariously low current ratio, underpinning the critical nature of forthcoming milestones for the SPAC’s viability.

Viking Acquisition Corp I, a Cayman Islands-based Special Purpose Acquisition Company (SPAC), has recently amended its Business Combination Agreement to refine share redemption sequencing and transaction structures ahead of its initial merger. Leveraging KingsRock’s extensive network and the management team's expertise, Viking is positioned to compete in a crowded acquisition market through proprietary sourcing advantages. The firm faces classic SPAC risks, including the finite 24-month timeframe to complete a business combination, but recent filings suggest active deal progress and strong liquidity underpin execution readiness.

Golden Growers Cooperative, founded in 1994 to add value for member corn growers via ownership in a corn wet-milling facility, secured long-term revenue through an exclusive lease agreement with Cargill. The cooperative’s structure, binding members to deliver over 15 million bushels annually, created a protected economic moat by aligning member interests with the ProGold facility. Recent years showed steady lease payments as the main income source, but challenges in renewing joint venture agreements led to a member-approved Plan of Liquidation in 2025. This will terminate operating revenues upon lease expiration in 2026 and result in asset sale proceeds distributed to members, marking a definitive pivot from ongoing operations to capital return.